Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Misoprostol to Optimizing Prevention of Cancer of the Cervix
NCT06669533Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Cervical Cancer (CC) comparing Misoprostol with Placebo (2 arms). Primary endpoint: Conversion rate from Type 3 transformation zone (TZ) to Types 1 or 2. Started Feb 2025; status: recruiting.
02
Drugs
misoprostol
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06669533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669533.